Who is sponsoring NCT03324945?

NCT03324945 is sponsored by Rachel Miller.

What drugs are being tested in NCT03324945?

Interventions in NCT03324945: Neurocognitive assessments.

What condition does NCT03324945 study?

NCT03324945 studies Chemotherapy-induced Cognitive Impairment.

Is NCT03324945 still recruiting?

NCT03324945 is currently completed. Last updated 12 November 2020.

Last reviewed 2020-11-12 · How we verify

NCT03324945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients

Completed NA Last updated 12 November 2020

What this trial tests

NA trial testing Neurocognitive assessments in Chemotherapy-induced Cognitive Impairment in 14 participants. Completed in 1 April 2019.

Timeline

1 August 2016

Primary endpoint
12 October 2018

1 April 2019

Quick facts

Lead sponsor	Rachel Miller
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	14
Start date	1 August 2016
Primary completion	12 October 2018
Estimated completion	1 April 2019
Sites	1 location across United States

Drugs / interventions tested

Neurocognitive assessments

Conditions studied

Chemotherapy-induced Cognitive Impairment — all drugs for Chemotherapy-induced Cognitive Impairment →

Sponsor

Rachel Miller — full company profile →

Who can join

18 and older, female only, with Chemotherapy-induced Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemotherapy-induced cognitive impairment (CICI), also known as "chemobrain," is a spectrum of neurocognitive deficits experienced during and after the administration of chemotherapy for cancer. The incidence of CICI is significant, affecting anywhere from 25 to 75% of survivors, and the biologic basis is unknown. This novel study is designed to address the questions of incidence and biological cause for CICI, while gaining a better understanding of the structural and functional effects of chemotherapy on the brain.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03324945 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rachel Miller
Last refreshed: 12 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03324945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing